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Inflammation in the middle ear mucosa, which can
be provoked by different primary factors such as
bacterial and viral infection, local allergic reactions
and reflux, is the crucial event in the pathogenesis of
otitis media with effusion (OME). Unresolved acute
inflammatory responses or defective immunoregula-
tion of middle inflammation can promote chronic
inflammatory processes and stimulate the chronic
condition of OME. Cytokines are the central molecu-
lar regulators of middle ear inflammation and can
switch the acute phase of inflammation in the
chronic stage and induce molecular 
/pathological
processes leading to the histopathological changes
accompanying OME. In this review we present cyto-
kines identified in otitis media, immunoregulatory
[interleukin (IL)-2, IL-10, transforming growth factor-
b]) and allergy associated (IL-4, IL-5, granulocyte 
/
macrophage colony-stimulating factor), as crucial
molecular regulators, responsible for chronic inflam-
mation in the middle ear and the chronic condition
of OME.
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Introduction
The immunoregulatory cytokines [interleukin (IL)-2,
IL-10, transforming growth factor (TGF)-b] and
allergy-associated cytokines [IL-4, IL-5, granulocyte /
macrophage colony-stimulating factor (GM-CSF)] are
mediators of the immune system, which are actively
involved in regulation of molecular and cellular
processes accompanying different types of inflamma-
tion.
IL-2 is the up-regulating cytokine, which stimulates
primarily the cell-mediated inflammatory response by
promoting growth, proliferation and differentiation
of T cells, B cells, natural killer (NK) cells, monocytes
and macrophages. It is secreted mainly by activated T
cells. IL-2 induces activation and rapid clonal expan-
sion of mature T cells, and cytokine production in T
cells, including interferon (IFN)-g and IL-4;
1 growth
of B cells and immunoglobulin (Ig) J-chain switching
and secretion of IgM in B cells;
2 proliferation,
production of IFN-g and cytolytic activity of NK
cells;
3 proliferation and differentiation of macro-
phage precursors;
4 and cytolytic activity of mono-
cytes.
5
In contrast to IL-2, IL-10 (known as the cytokine
synthesis inhibitory and macrophage deactivating
factor) down-regulates the immune reactions accom-
panying acute inflammation and limits the duration of
inflammatory responses. IL-10 can also promote and
regulate chronic inflammatory processes. IL-10 is
produced by a variety of cell types, including CD4
 
T cells, activated CD8
  T cells and activated B cells.
The main anti-inflammatory activities of IL-10*/
namely, inhibition of cytokine production in macro-
phages, neutrophils, T cells and NK cells,
6 9 and
inhibition of the macrophage /monocyte activation
and the antigen presentation abilities of these
cells
10*/lead to the resolution of inflammation.
However, if the acute inflammatory process has not
been resolved, IL-10 can induce humoral inflamma-
tory reactions such as the immunoglobulin isotype
switching in B cells
11,12 and differentiation of B cells
into plasma cells,
13 and thus promote switching of
inflammation in the chronic stage.
TGF-b, produced by T cells, platelets and mono-
cytes, plays an important role in regulation of the
inflammatory processes and in tissue reparation. The
effects of TGF-b depend on the differentiation state of
the responsive cells.
14 TGF-b, as well as IL-10,
participates in resolution of acute inflammation by
inhibiting antigen presentation and cytokine produc-
tion in macrophages,
15 and suppressing proliferation
of T cells and NK cells and cytokine production in
activated T cells.
14 Simultaneously, TGF-b recruits
monocytes to the site of inflammation and up-
regulates their pro-inflammatory activity; secretion
of cytokines and growth factors, in particular.
14 The
contradictory effects of TGF-b on monocyte/macro-
phage lineage, such as up-regulation of monocyte
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75functions and deactivation of macrophages, demon-
strate the highly coordinated role of TGF-b in
regulation of inflammatory responses.
The immunoregulatory and allergy-associated cy-
tokine IL-4, produced by CD4
  T cells, mast cells and
basophils, is actively involved in regulation of
different types of inflammation. IL-4 up-regulates
humoral inflammatory responses by inducing growth
of B cells, isotype switching in activated B cells and
differentiation of B cells into antibody producing
plasma cells.
16 IL-4 also stimulates the cell-mediated
inflammatory processes by promoting growth of
activated T cells
17 and enhancing the development
of virus-specific cytotoxic T cells.
18 Simultaneously,
IL-4 possesses powerful anti-inflammatory effects. In
particular, IL-4 controls numerous molecular pro-
cesses in monocytes, macrophages and neutrophils,
which down-regulate production and secretion of the
pro-inflammatory cytokines tumour necrosis factor
(TNF)-a, IL-1 and IL-8,
19 21 deactivate inflammatory
macrophages and lead to suppression of acute
inflammation. IL-4 can also induce switching of acute
inflammation in the chronic stage owing to its ability
to up-regulate expression of the mannose receptor
on activated macrophages.
22 The mannose receptor
promotes fusion of activated macrophages and for-
mation of giant multinucleated cells in the zone of
inflammation
23 that create the cellular background
for manifestation of chronic inflammation.
IL-5 is an important regulator of the humoral
immune response and is produced by CD4
  T cells
as well as NK cells.
24 Being a late regulating factor in
differentiation of B cells, IL-5 plays an essential role
in cytokine-induced production and secretion of
immunoglobulins and supports humoral inflamma-
tory reactions such as production and secretion of
IgA.
25 IL-5 is also the allergic cytokine, which by
stimulating production, activation, differentiation and
migration of eosinophils creates a strong molecular
background for eosinophilic inflammation.
26,27
GM-CSF regulates proliferation and maturation of
granulocyte and macrophage precursors and acti-
vates mature neutrophils, eosinophils and macro-
phages,
28 and thus participates in different types of
inflammation.
29 Monocytes, T cells, fibroblasts and
endothelial cells activated by macrophage cytokines
IL-1b or TNF-a produce GM-CSF. The GM-CSF
enhances neutrophil phagocytosis, enhances release
of chemotactic factors by neutrophils,
30 induces
production of the pro-inflammatory cytokines by
macrophages and increases their function as anti-
gen-presenting cells,
31 and in this way promotes
acute inflammatory reactions. In the presence of IL-
4, GM-CSF can initiate a specific differentiation of
monocytes into osteoclast-like multinucleated giant
cells
32 that create a background for chronic inflam-
mation. GM-CSF can also contribute to allergic
inflammation by promoting growth, prolonged sur-
vival and activation of eosinophils and basophils.
33
Both groups of cytokines, the immunoregulatory
IL-2, IL-10 and TGF-b and the allergy-associated IL-4,
IL-5 and GM-CSF, have been identified in otitis media
and their presence is the evidence of their participa-
tion in regulation of local inflammatory processes.
These cytokines can switch the acute phase of middle
ear inflammation into the chronic stage and lead to
the chronic condition of otitis media with effusion
(OME).
OME: a brief description
OME, the commonest cause of childhood deafness in
the developed world, is a chronic inflammatory
condition of the middle ear cleft with repetitive
recurrences of acute middle ear inflammation. The
disease is characterized by a middle ear effusion that
persists for months to years, cannot be cleared by the
normal mucociliary transport mechanisms and is
must usually removed by surgical operation.
A surgical procedure, which includes myringot-
omy, aspiration of fluid and the insertion of ventila-
tion tubes (grommets) in the anterior tympanic
membrane (Fig. 1), is the most effective option in
treatment of OME. The main problem with ventilation
tubes is secondary infection and post-operative
otorrhea, which can be managed using antibiotic
eardrops.
34,35 However, increasing antibiotic resis-
tance of bacterial pathogens
36 and possible ototoxi-
city of topical antibiotics
37 can complicate the
antimicrobial therapy in post-surgical management
of otitis media. Other non-surgical approaches in
treatment and prophylaxis of OME include traditional
methods, such as combined steroid /antimicrobial
therapy
38,39 and polyvalent pneumococcal vaccina-
tion,
40,41 and relatively new methods based on herbal
medicine
42,43 and homeopathy.
44,45
The chronic condition of otitis media is associated
with proliferative changes in the middle ear tissues,
especially in the surface middle ear mucosa, which is
presented in OME as a modified pseudostratified
epithelium,
46 where basal cells are differentiating into
goblet cells,
47 goblet cells are proliferating with
enhanced secretory activity
48 and formation of mucus
glands occurs
49,50 (Fig. 1).
Goblet cells produce and secrete mucins, which
are important glycoproteins in the mucociliary trans-
port system of the middle ear and are the main
component of middle ear effusions, responsible for
the viscous properties of effusions.
51,52 However,
under disease conditions, alterations that occur in
the middle ear and eustachian tube mucin metabo-
lism,
53 in the structure of mucin glycoproteins
54,55
and in the glycoconjugate expression in cilia and
goblet cells
56 promote the dysfunction of the normal
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effusion in the middle ear cleft.
The expression of several mucins has been de-
tected in OME.
53,57 However, overproduction of only
two mucins has been observed in otitis media;
namely, the membrane-bound MUC4
53 and the
secreted MUC5B.
53,55,58,59 Another secreted mucin
(MUC5AC) is always presented in effusions, but in
varying amounts,
53,55,57,60 and its levels maybe linked
to levels of the pro-inflammatory cytokines TNF-a,
IL-6 and IL-8, which can promote different levels of
MUC5AC secretion.
61,62
The initial step in the pathogenesis of OME is the
inflammatory process in the middle ear mucosa.
Bacteria,
63,64 viruses,
65,66 allergic reactions
67,68 and
even gastroesophageal reflux
69 71 in tandem with
predisposing factors such as eustachian tube dysfunc-
tion,
72 cleft palate
73 and obstructive adenoids
74 can
stimulate the middle ear inflammation.
Different groups of inflammatory mediators were
identified in the human middle ear mucosa, fluids
and effusions. A lot of different mediators participate
in initiation and early stages of the middle ear
inflammation, including arachidonic acid metabolites
FIG. 1. Anatomy of the ear, schematic structure of the middle ear epithelium and mucus gland. (A) Anatomy of the ear: OE,
outer ear; ME, middle ear; IE, inner ear; TM, tympanic membrane; ET, Eustachian tube; NP, nasopharynx. (B) There are two
types of epithelium in the middle ear. The major part of middle ear is lined with simple squamous epithelium (1B). Near the
Eustachian tube, epithelium of the middle ear is gradually transformed into pseudostratiﬁed columnar type (2B), some of
which is ciliated. (C) Schematic structure of the mucus gland in the middle ear mucosa. Mucus glands develop as basal cells
grow down into the lamina propria and differentiate into goblet cells.
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Mediators of Inflammation Vol 13  2004 77(prostaglandin E2 and leukotrienes LT-B4, LT-C4),
75,76
histamine,
77,78 platelet-activating factor,
79 surface cell
adhesion molecules (intercellular adhesion molecule-
1, vascular cell adhesion molecule-1, endothelial
leukocyte adhesion molecule-1, platelet endothelial
cell adhesion molecule),
80,81 soluble cell adhesion
molecules (soluble intercellular adhesion molecule-1
and soluble vascular cell adhesion molecule-1),
82,83
chemokine RANTES,
84 complement C3a anaphyla-
toxin
85 and interferon-g.
86
However, cytokines are the key mediators of the
middle ear inflammation. Cytokines regulate different
stages of inflammation, are responsible for resolution
of inflammation and can initiate local molecular
processes leading to histopathological changes in
the middle ear mucosa and submucosa, and the
chronic condition of otitis media. Different groups of
cytokines have been identified in the middle ear
effusions and mucosa: the pro-inflammatory TNF-a,
IL-1b, IL-6 and IL-8; the immunoregulatory IL-2, IL-10
and TGF-b; and the allergy-associated IL-4, IL-5 and
GM-CSF.
The pro-inflammatory cytokines and their partici-
pation in the pathogenesis of otitis media have been
already discussed,
87 and are more related to the acute
phase of middle ear inflammation. In the present
review we have analysed the immunoregulatory and
the allergy-associated cytokines in otitis media,
which, by providing the cellular and molecular
background for the chronic inflammation in middle
ear, promote the chronic condition of OME.
The immunoregulatory cytokines IL-2,
IL-10, TGF-b and their cellular and molecular
networks in OME
IL-2 in otitis media
IL-2 has been detected in middle ear effusions from
children with chronic OME at high concentration
(greater than 300 pg/ml).
88 The analysis of peripheral
blood immunologic pattern in patients with persis-
tent middle ear effusions
89,90 showed the following:
(1) the number of CD4
  and CD8
  T lymphocytes
was decreased and the T-cell subset ratio (CD4
 /
CD8
 ) was reduced; (2) proliferative responses of
blood T cells were diminished; and (3) generation of
IL-2 by peripheral blood lymphocytes was decreased.
Another immunologic investigation of children with
recurrent otitis media revealed a consistent inability
of adenoidal T cells to turn on B cells to mature into
immunoglobulin-secreting plasma cells that has been
explained by defective production of IL-2 in ade-
noids.
91 This assumption was confirmed by cytokine
assay of IL-2, which has been done simultaneously in
nasopharyngeal lymphoid tissues and in peripheral
blood of children with recurrent otitis. The adenoidal
lymphocytes produced significantly less IL-2 com-
pared with the patient’s peripheral blood lympho-
cytes.
92 It has been assumed that poor production of
IL-2 in adenoidal tissues is probably linked to a
deficiency of IL-2 production in the middle ear
tissues, and that could be associated with the
persistence of OME. Thus, general and/or local
deficiency of the IL-2 production could induce
defective immunoregulation of the middle ear in-
flammation and promote the persistence of OME.
The investigation of IL-2 in experimental models of
otitis media showed the involvement of IL-2 in
regulation of acute inflammation because: (1) the
IL-2 producing cells were predominant in acute OME
compared with chronic OME,
93 and (2) recombinant
IL-2 trans-tympanically injected into the middle ear of
normal guinea pigs caused the inflammatory middle
ear effusion within 24 h, which cleared by 72 h after
inoculation.
94 However, differing degrees of respon-
siveness of effusion production were observed fol-
lowing the instillation of IL-2 in the middle ear,
95
varying from pronounced middle ear effusion caus-
ing rather severe mixed hearing loss to complete lack
of effusion, and IL-2 was detected in all the middle
ear effusions in experimental OME with signs of
sensorineural hearing loss.
96
By analysis of clinical and experimental data we
can propose the following conclusions about the role
of IL-2 in OME:
1. IL-2 is involved in regulation of the middle
ear inflammation and, as the main T-cell
growth and differentiation factor, IL-2 can
support acute and chronic inflammatory
processes in the middle ear.
2. IL-2 can regulate local acute inflammatory
response by inducing activation, differentia-
tion of T cells and production of the pro-
inflammatory (IL-1b, IL-6) and anti-inflam-
matory cytokines (IL-10, TGF-b) by activated
T cells (Fig. 2).
3. The deficiency of local or general IL-2
production can suppress reactions of acute
inflammation and promote persistence of
OME, which can develop with time into the
chronic OME (Fig. 3).
4. The excessive production of IL-2 can pro-
voke chronic cell-mediated and (or) hu-
moral inflammatory processes (proliferation
of activated T cells, increased production of
cytokines IL-4, IL-5 and GM-CSF by prolif-
erated T cells, immunoglobulin-switching
and IgM secretion in B cells), which will
induce switching of the middle ear inflam-
mation in the chronic stage with subsequent
development of chronic OME (Fig. 3).
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78 Mediators of Inflammation Vol 13  2004FIG. 2. Cytokine regulation of acute inﬂammatory response in the middle ear. Initiation of inﬂammation includes activation of
macrophages, which, by presenting antigen, interact with T cells and induce the T-cell activation. The activated macrophages
(aMf) produce the primary pro-inﬂammatory cytokines IL-1b and TNF-a, which up-regulate secretion of IL-8 by goblet cells
and endothelial cells and secretion of GM-CSF by activated macrophages. IL-8 and GM-CSF promote activation of neutrophils
and macrophages*/the main effector cells of acute inﬂammation. IL-8 induces chemotaxis and accumulation of neutrophils,
and GM-CSF increases neutrophil phagocytosis and inﬂammatory activity of macrophages. Simultaneously the activated T
cells (aTcells) produce many cytokines including IL-1b, IL-6, IL-2, IL-10 and TGF-b. IL-2 enhances further activation and
differentiation of T cells. IL-1b and IL-6 join the ongoing inﬂammation and enhance it. IL-10 and TGF-b keep under control
inﬂammatory processes, and when the antigen is completely destroyed they inhibit activities of neutrophils and macrophage
and production of the inﬂammatory cytokines IL-1b, IL-6, IL-8 and TNF-a, and thus provide resolution of inﬂammation.
Overproduction of the immunoregulatory cytokines IL-2, IL-10 and TGF-b in the course of middle ear inﬂammation will
promote humoral and cell-mediated chronic processes and switching of inﬂammation in the chronic stage.
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The clinical investigations demonstrated the involve-
ment of IL-10 in chronic otitis media.
97,98 IL-10 was
identified in middle ear effusions from children
undergoing tympanostomy tube placements and its
mean concentration was 569 /58.7 pg/ml.
97 It has
been assumed that the presence of IL-10 in middle
ear effusions might be one of the causes of a lack of
clinical features of acute inflammation and could lead
to a chronic inflammatory state. Chronic otitis media
has been also associated with dysregulated local
production of IL-10.
98 Patients with chronic otitis
media showed high levels of IL-10 ( /100 pg/ml)
produced by sinus lavage cell culture and simulta-
neously low production of IL-10 by peripheral blood
mononuclear cells.
Investigations of cytokine profiles in different
experimental models of OME showed a rapid
appearance of IL-10 in the early stages of acute otitis
media
99 103 and that IL-10 in mucosa was produced
predominantly by CD4
  T cells.
104 Streptococcus
pneumoniae induced expression of IL-10 mRNA in
middle ear mucosa within 1 /2 days after inocula-
tion.
99,100 Lipoteichoic acid, one of the components
present within the cell wall layer of most Gram-
positive bacteria,
101 and non-typeable Haemophilus
influenzae (NTHi)
102,103 induced the expression of
IL-10 mRNA in middle ear mucosa even faster, within
6 h after inoculation. It is interesting to note that the
expression of IL-10 mRNA followed the expression of
TNF-a and IL-6 mRNAs,
99,100 and sometimes occurred
simultaneously with the pro-inflammatory cyto-
kines.
101,102
Thus, clinical and experimental data about IL-10 in
OME lead to the following conclusions:
1. IL-10 is involved in regulation of the middle
ear inflammatory response induced by bac-
terial infection.
2. The expression of IL-10 in acute otitis media
is up-regulated shortly after or even simul-
FIG. 3. Cellular and molecular consequences of the unbalanced production of IL-2 in the course of the middle ear inﬂammation
leading to the chronic condition of OME.
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cytokines, TNF-a and IL-6. That is, the
evidence of initiation of corrective immu-
noregulation in the middle ear mucosa,
because IL-10 as the main anti-inflammatory
cytokine, can down-regulate the local po-
pulation of inflammatory cells, macrophages
and neutrophils, and production of the pro-
inflammatory cytokines TNF-a, IL-1b, IL-6,
IL-8 and promote resolution of inflammation
(Fig. 2).
3. If the acute inflammatory response is not
resolved correctly, the prolonged presence
of IL-10 in the zone of inflammation can
provoke the amplification of chronic hu-
moral inflammatory processes, such as in-
creased secretion of immunoglobulins,
especially IgA, by activated B cells and
possible generation of plasma cells, in the
presence of IL-4 (Fig. 4). In this way, IL-10
can contribute to switching of the disease
into the chronic stage.
4. The deficiency of IL-10 in acute otitis media
can also lead to chronic condition of OME,
because shortage of IL-10 will promote
overproduction of the inflammatory cyto-
kines, especially IL-1b, TNF-a and IL-6,
which can induce tissue damage and irre-
versible changes in the middle ear mucosa
(Fig. 4).
General conclusions about the role of IL-2 and
IL-10 in an aetiology of OME
Both cytokines, IL-2 and IL-10, participate in ba-
lanced immunoregulation of the middle ear inflam-
matory response. IL-2 up-regulates cellular and
molecular events, accompanying acute inflammation,
whereas IL-10 down-regulates acute inflammatory
reactions and promotes resolution of inflammation.
Any imbalance in production of these cytokines will
induce chronic inflammatory processes (cell-
mediated or humoral, or both) or stimulate uncon-
trolled inflammatory-related damage of the middle
ear tissues (Figs 3 and 4).
Thus, IL-2 and IL-10 can be considered as the key
cytokine mediators, regulating switching of the acute
phase of middle ear inflammation in the chronic
stage, which will lead to the chronic condition of
OME.
TGF-b in otitis media
Clinical investigations of TGF-b in OME showed its
relation to chronic otitis media.
105,106 The identifica-
tion of TGF-b in serous and mucoid middle ear
effusions was associated with a history of previous
FIG. 4. Cellular and molecular consequences of the unbalanced production of IL-10 in the course of the middle ear
inﬂammation leading to the chronic condition of OME.
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105 Investigation of
growth factors in tympanic membrane perforations
showed that TGF-b could promote development of
the fibrotic scar at the perforation margin, explaining
the deficient healing pattern of tympanic membranes
in chronic otitis media.
106
However studies of cytokines in experimental
OME demonstrated the presence of TGF-b also in
acute otitis media.
100,102,103 The expression of TGF-b
mRNA was up-regulated in acute otitis media caused
by S. pneumoniae
100,102 and NTHi infections,
102,103
and was detected early during the course of acute
inflammation, within 24 h after inoculation, together
with cytokines IL-1, TNF-a and IL-10. However, the
highest mRNA levels for TGF-b were recorded
considerably later, on days 6 and 28, for the NTHi-
infected and pneumococcus-infected animals, re-
spectively, and its expression continued even after
resolution of acute otitis media.
102
TGF-b regulates host response in infectious dis-
eases through the TGF-b-activated kinase 1
107 and
TGF-b-Smad signaling pathway.
108 It has been shown
that NTHi, a major human bacterial pathogen of otitis
media, strongly induced up-regulation of MUC5AC
mucin in human epithelial cells. This induction
occurred via activation of the Toll-like receptor 2-
MyD88-dependent p38 mitogen-activated protein
kinase (MAPK) pathway. However, activation of
TGF-b-Smad signaling by TGF-b resulted in down-
regulation of p38 MAPK by inducing MAPK phopha-
tase-1, and subsequent down-regulation of MUC5AC
transcription.
108 TGF-b thereby acted as a negative
regulator of MUC5AC mucin gene expression. This is
a very significant fact in understanding the role of
TGF-b in otitis media, because varying levels of the
secreted mucin MUC5AC are presented in the middle
ear mucosa and effusions in patients with
OME.
53,55,57
By analysis of these data we can make the
following conclusions about the role of TGF-b in
OME:
1. TGF-b participates in regulation of the mid-
dle ear inflammation.
2. TGF-b is a negative regulator of acute
inflammation in the middle ear. Early activa-
tion of TGF-b together with another anti-
inflammatory cytokine, IL-10, in the course
of acute otitis media demonstrates the in-
volvement of TGF-b in the correct resolution
of acute inflammatory response. TGF-b as
well as IL-10 can inactivate macrophages
and inhibit pro-inflammatory cytokine pro-
duction at the site of inflammation (Fig. 2).
3. TGF-b can be also involved in down-regula-
tion of bacterial-induced MUC5AC mucin
production, and that is the additional evi-
dence for TGF-b as a negative regulator of
the acute middle ear inflammation.
4. The high level of TGF-b expression detected
on later stages of the middle ear inflamma-
tion and after shows participation of TGF-b
in repair of damaged tissues.
5. The presence of TGF-b in chronic otitis
media demonstrates the involvement of
TGF-b in regulation of chronic inflammatory
response in the middle ear. The overproduc-
tion of TGF-b can promote chronic inflam-
matory processes in the middle ear, both
cell-mediated and humoral (Fig. 5). The cell-
mediated response, induced by TGF-b, can
develop in the following way: excessive
accumulation of monocytes activated by
TGF-b leads to excessive amount of macro-
phages and their activation in the presence
of GM-CSF. These activated macrophages in
the zone of inflammation, in the presence of
IL-4, can fuse and generate the multinu-
cleated giant cells, which are the cellular
background for chronic inflammation. Hu-
moral inflammatory processes, which can be
up-regulated by TGF-b, include the in-
creased secretion of immunoglobulins, IgA
in particular, especially in the presence of IL-
10.
6. The prolonged expression of TGF-b in the
zone of inflammation can lead to excessive
accumulation of fibroblasts and result in
progressive fibrosis, which is analogous to
unregulated tissue repair.
Thus, TGF-b can contribute to the pathogenesis
and persistence of chronic OME in many ways.
The allergy-associated cytokines IL-4, IL-5
and GM-CSF and their cellular and
molecular networks in OME
IL-4 in otitis media
IL-4 was identified in the middle ear effusions of
children with persistent OME
109 and in atopic chil-
dren with OME undergoing myringotomy and venti-
lation tube placement.
110 The cytokine analysis of
effusions showed a higher mean level of IL-4 in the
allergy-positive group compared with the allergy-
negative group
109 and a higher percentage of cells
expressing IL-4 in atopic patients with OME com-
pared with that seen in non-atopic patients.
110 A
higher level of IL-4 in effusions correlated with
predominance of T lymphocytes, which was the
sign of chronic inflammation and was also related
to the atopic background of patients with OME.
110 In
effusions of non-atopic patients, the level of IL-4 was
M. G. Smirnova et al.
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109 de-
monstrated signs of an acute inflammatory response.
Investigation of adenoids in patients with recurrent
otitis media
92,111 resulted in the following important
findings: (1) expression and secretion of IL-4 was
detected in adenoids; (2) adenoidal lymphocytes
produced the same level of IL-4, or even slightly
more, compared with the patient’s peripheral blood
lymphocytes;
92 and (3) the epsilon germline tran-
scripts for IgE were detected in the adenoids and the
level of IgE epsilon germline transcript expression
was dependent on the level of IL-4 mRNA expres-
sion.
111 This local IL-4-induced immunoglobulin class
switching to IgE in the adenoids was considered the
essential molecular process contributing to chronic
inflammation in the middle ear and promoting the
pathogenesis and persistence of OME.
Thus, IL-4 was presented in both groups of patients
with OME, allergic and non-allergic. However, local
overproduction of IL-4 was associated predominantly
with an allergic background of patients.
Studies on IL-4 in experimental OME
93,112 demon-
strated the involvement of IL-4 in regulation of
different types of otitis media. In trans-tympanically
challenged animals the expression of IL-4 was
detected during acute and chronic otitis media, with
the predominance of IL-4
  cells in the acute form.
93
The trans-tympanical injection of soluble receptors
FIG. 5. Consequences of the overproduction of TGF-b in the course of the middle ear inﬂammation.
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dysfunction and formation of effusion in the middle
ear cleft.
112
The involvement of IL-4 in regulation of MUC5AC
and MUC5B mucin gene expression and secretion
has been shown in human airways.
113 115 The
secreted mucins, MUC5AC and MUC5B, are pre-
sented in the middle ear mucosa and effusions in
patients with chronic OME.
53,55,57 60 Although rela-
tionships between IL-4 and production of MUC5AC
and MUC5B mucins in the course of otitis media have
not been investigated, the ability of a soluble receptor
for IL-4 to prevent Eustachian tube dysfunction and
formation of effusions in the middle ear cleft
112
demonstrated the potential involvement of IL-4 in
the regulation of the middle ear mucin metabolism.
All these data allow us to make the following
conclusions about the role of IL-4 in OME:
1. IL-4 is involved in regulation of different
types of otitis media.
2. IL-4 is one of the cytokines responsible for
an allergic type of inflammation owing its
ability to induce local immunoglobulin class
switching to IgE (Fig 6).
3. IL-4 can support local humoral inflammatory
responses by increasing production and
secretion of immunoglobulins in activated
B cells (Figs 4 and 6).
4. IL-4 can also support cell-mediated chronic
inflammation in the middle ear by promot-
ing generation of multinucleated giant cells
(Figs 5 and 6), although it is necessary to
note that giant cells in OME have not been
investigated.
5. IL-4 can also participate in the regulation of
mucin metabolism and the mucociliary
transport system in middle ear inflammation.
Thus, IL-4 is the important regulator of cellular and
molecular processes, accompanying different types
and different stages of the middle ear inflammation,
and an important factor contributing to chronic
condition and persistence of OME.
IL-5 in otitis media
IL-5 was detected in the middle ear mucosa and
effusions in atopic patients with persistent
OME.
110,116,117 The expression of IL-5 mRNA in
mucosa was up-regulated and correlated with in-
creased expression of major basic protein (cell
marker for eosinophils) and CD3 (cell marker for
activated T lymphocytes).
116 Examination of the
cytokine profile in the middle-ear specimens showed
an increased number of cells expressing IL-5 and its
correlation with the percentage of eosinophils and T
lymphocytes.
110 Correlation between the percentage
of eosinophils and levels of IL-5 in effusions was
particularly striking in OME patients with asthma,
117
suggesting that middle ear eosinophilia could be
dependent not only on the local, but also on the
general level of IL-5 production. The percentage of
cells expressing IL-5 in effusions of atopic patients
was the same or slightly higher compared with cells
expressing IL-4;
110 this was evidence that both
cytokines IL-5 and IL-4 contributed to development
of allergic inflammation in the middle ear.
Thus, overproduction of IL-5 in OME is associated
with the atopic background of patients, and IL-5
together with IL-4 is responsible for an allergic type
of inflammation in the middle ear (Fig. 6). This
assumption was confirmed in an experimental model
of OME,
112 where the late-phase allergic inflamma-
tory response was prevented by pretreatment with IL-
5 antibodies or soluble receptors for IL-4.
However, the involvement of IL-5 in regulation of
the non-allergic inflammatory response in the middle
ear should not be ignored. The production of IL-5
was detected in effusions of non-atopic patients with
OME,
110,117 although it was significantly less com-
pared with atopic patients. Analysis of immunoregu-
latory cytokines in experimental models of OME
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demonstrated the absence of IL-5 in acute otitis
media and significant up-regulation of IL-5 produc-
tion in chronic otitis media, where IL-5
  cells were
numerous. Thus, the presence of IL-5 in OME of non-
allergic patients shows the involvement of IL-5 in
regulation of non-allergic chronic inflammatory reac-
tions in the middle ear, where IL-5 can support
humoral processes such as increased production
and secretion of immunoglobulins, IgA in particular
(Fig. 6).
Thus, IL-5 can be considered the late mediator of
middle ear inflammatory response, regulating allergic
inflammation and increasing humoral inflammatory
processes, which contribute to the chronic condition
of OME.
GM-CSF in otitis media
Our knowledge about GM-CSF in OME is insufficient.
However, the involvement of GM-CSF in regulation
of middle ear inflammation has been shown as GM-
CSF was identified in effusions of acute purulent and
chronic otitis media.
118 The level of GM-CSF in acute
otitis media was higher compared with the chronic-
type otitis media.
Despite a lack of experimental data about GM-CSF
in OME, this cytokine could participate in regulation
of different stages of the middle ear inflammation.
GM-CSF was identified in acute otitis media, where it
could activate matured neutrophils and macrophages
and support the acute inflammatory response (Fig. 2).
GM-CSF in the presence of IL-4 can induce
monocyte differentiation towards generation of mul-
M. G. Smirnova et al.
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cellular background for chronic middle ear inflam-
mation (Fig. 5).
Finally, GM-CSF being the eosinophil survival-
promoting cytokine together with IL-5 can up-reg-
ulate allergic eosinophil-mediated inflammation in
the middle ear (Fig. 6). However, in the past year of
investigations GM-CSF has been shown as a potential
down-regulator of allergic inflammation, because
GM-CSF induced apoptosis of human eosinophils
through the eosinophil receptor Siglec-8 (sialic acid
binding immunoglobulin-like lectin).
119
Thus, GM-CSF can be a very important regulator of
the middle ear inflammation and additional experi-
mental work needs to be done to clarify the exact
role of this cytokine in the pathogenesis of chronic
OME.
Immunoglobulins in chronic OME
Different types of immunoglobulins, namely IgM,
IgG, IgA, secretory IgA and IgE, have been identified
in effusions and middle ear fluid of chronic
OME.
120 123 The effusion level of IgM in some
patients with chronic otitis media was markedly
elevated.
120 The mucoid type of effusions contained
a high level of IgG, IgA
121 and IgE.
124 Comparison of
the immunoglobulin levels measured in effusions and
in sera showed that, in many cases, the effusion level
of secretory IgA
122 and IgE
125 was significantly higher
than the corresponding serum level, and this was the
evidence of local overproduction of immunoglobu-
lins in the middle ear.
The immunologic investigation of effusions de-
tected the immune complexes of IgG (IgG /ICs) and
FIG. 6. Cellular and molecular networks of the allergy-associated cytokines leading to the chronic condition of OME.
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media.
126,127 The highest level of IgG /ICs was found
in subacute cases, whereas IgA /ICs were predomi-
nant in chronic OME. The immunoglobulin immune
complexes provided the prolongation of inflamma-
tory process in the middle ear.
The presence of immunoglobulins in chronic OME
was associated mainly with the bacterial in-
fection.
128 131 IgG and IgA antibodies specific to
Hemophilus influenzae and S. pneumoniae,
128 IgG,
IgM, IgA and secretory IgA antibodies specific to
outer membrane antigens of Moraxella catarrha-
lis,
129 and Staphylococcus aureus-harboured bac-
teria, intensely coated with secretory IgA and IgG
antibodies,
130,131 were identified in chronic effusions.
Only one type of immunoglobulins, the secretory
IgA, was identified in effusions infected with respira-
tory viruses.
132
The presence of IgE in chronic OME has not been
always associated with local allergic inflamma-
tion.
124,133 However, local overproduction of IgE
was usually accompanied by local allergic reactions,
such as degranulation of mast cells found in the
middle ear biopsy specimens
124 and expression of
IgE on mast cells detected in nasal mucosa specimens
from patients with OME.
134
Thus, the activity of immunoglobulins in chronic
OME is evidence of chronic humoral inflammatory
processes in the middle ear, which is obviously
controlled by cytokines. Correlation between the
levels and types of immunoglobulins and the im-
munoregulatory and allergy-associated cytokines in
chronic OME has not been investigated. However,
the presence of the main types of immunoglobulins,
IgM, IgG, IgA, secretory IgA and IgE, in effusions is
indirect evidence that cytokines IL-2, IL-10, TGF-b, IL-
4 and IL-5, which are involved in regulation of
immunoglobulin production and secretion in gen-
eral,
2,11,12,16,25 participate also in local production
and secretion of immunoglobulins and regulate
humoral immune reactions during the course of
middle ear inflammation (Figs 3 /6).
Concluding remarks
The immunoregulatory cytokines and the allergy-
associated cytokines can be considered the key
regulators of the middle ear inflammation responsible
for the molecular and cellular background of chronic
OME.
The immunoregulatory cytokines IL-2, IL-10 and
TGF-b initiate and support molecular switching of the
acute phase of inflammation in the chronic stage,
whereas the allergy-associated cytokines IL-4, IL-5
and GM-CSF very probably provide the molecular
and cellular background for chronic humoral, cell-
mediated and allergic inflammatory processes in the
middle ear, which lead to the chronic condition of
OME.
However, it is necessary to note that additional
experimental work needs to be done in order: (1) to
elucidate the molecular mechanisms of cytokine
regulation of the middle ear inflammation; and (2)
to analyse the possibility of anti-cytokine therapy in
clinical treatment of OME.
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